Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer

References

• American Cancer SocietyCancer Facts and Figures 2016 Available from: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdfAccessed March 22, 2016
   Google Scholar
• American Cancer SocietyBreast Cancer Facts and Figures 2015–2016 Available from: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-046381.pdfAccessed March 29, 2016
   Google Scholar
• MaoCYangZYHeBFToremifene versus tamoxifen for advanced breast cancerCochrane Database Syst Rev20127CD00892622786516
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network IncNCCN Clinical Practice Guidelines in Oncology Breast Cancer. Version 1WashingtonNational Comprehensive Cancer Network Inc2014
   Google Scholar
• NabholtzJMBuzdarAPollakMAnastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study GroupJ Clin Oncol200018223758376711078488
   PubMed Web of Science ®Google Scholar
• NabholtzJMBonneterreJBuzdarARobertsonJFThurlimannBAnastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety resultsEur J Cancer200339121684168912888362
   PubMed Web of Science ®Google Scholar
• ParidaensRJDirixLYBeexLVPhase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative GroupJ Clin Oncol200826304883489018794551
   PubMed Web of Science ®Google Scholar
• MouridsenHGershanovichMSunYPhase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer GroupJ Clin Oncol200321112101210912775735
   PubMed Web of Science ®Google Scholar
• GibsonLLawrenceDDawsonCBlissJAromatase inhibitors for treatment of advanced breast cancer in postmenopausal womenCochrane Database Syst Rev20094CD00337019821307
   PubMed Web of Science ®Google Scholar
• OsborneCKSchiffRMechanisms of endocrine resistance in breast cancerAnnu Rev Med20116223324720887199
   PubMed Web of Science ®Google Scholar
• ChlebowskiRTChanging concepts of hormone receptor-positive advanced breast cancer therapyClin Breast Cancer201313315916623228361
   PubMed Web of Science ®Google Scholar
• BarriosCForbesJFJonatWThe sequential use of endocrine treatment for advanced breast cancer: where are we?Ann Oncol20122361378138622317766
   PubMed Web of Science ®Google Scholar
• Aromasin (exemestane tablets) [package insert]New York, NYPharmacia & Upjohn Company2014
   Google Scholar
• TokunagaEKimuraYMashinoKActivation of PI3K/Akt signaling and hormone resistance in breast cancerBreast Cancer200613213714416755107
   PubMedGoogle Scholar
• MillerTWHennessyBTGonzalez-AnguloAMHyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancerJ Clin Invest201012072406241320530877
   PubMed Web of Science ®Google Scholar
• BeeramMTanQTTekmalRRRussellDMiddletonADeGraffenriedLAAkt-induced endocrine therapy resistance is reversed by inhibition of mTOR signalingAnn Oncol20071881323132817693645
   PubMed Web of Science ®Google Scholar
• Afinitor (everolimus) tablets for oral administration. Afinitor Disperz (everolimus tablets for oral suspension) [package insert]East Hanover, NJNovartis Pharmaceuticals Corporation22016
   Google Scholar
• BaselgaJCamponeMPiccartMEverolimus in postmenopausal hormone receptor-positive advanced breast cancerN Engl J Med2012366652052922149876
   PubMed Web of Science ®Google Scholar
• YardleyDANoguchiSPritchardKIEverolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysisAdv Ther2013301087088424158787
   PubMed Web of Science ®Google Scholar
• ChiaSGradisharWMauriacLDouble-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECTJ Clin Oncol200826101664167018316794
   PubMed Web of Science ®Google Scholar
• Di LeoAJerusalemGPetruzelkaLResults of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancerJ Clin Oncol201028304594460020855825
   PubMed Web of Science ®Google Scholar
• Faslodex (fulvestrant) injection [package insert]Wilmington, DEAstraZeneca Pharmaceuticals LP2012
   Google Scholar
• Ibrance (palbociclib) capsules, for oral use [package insert]New York, NYPfizer Labs2015
   Google Scholar
• FinnRSCrownJPLangIThe cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 studyLancet Oncol2015161253525524798
   PubMed Web of Science ®Google Scholar
• ChenZMaricicMBassfordTLFracture risk among breast cancer survivors: results from the Women’s Health Initiative Observational StudyArch Intern Med2005165655255815767532
   PubMedGoogle Scholar
• VehmanenLSaartoTElomaaIMakelaPValimakiMBlomqvistCLong-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatmentEur J Cancer200137182373237811720830
   PubMed Web of Science ®Google Scholar
• FuleihanGSalamounMMouradYAPamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trialJ Clin Endocrinol Metab20059063209321415769994
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNMartinoSA randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancerN Engl J Med2003349191793180214551341
   PubMed Web of Science ®Google Scholar
• SantenRJClinical review: effect of endocrine therapies on bone in breast cancer patientsJ Clin Endocrinol Metab201196230831921147884
   PubMed Web of Science ®Google Scholar
• MinceyBADuhMSThomasSKRisk of cancer treatment- associated bone loss and fractures among women with breast cancer receiving aromatase inhibitorsClin Breast Cancer20067212713216800971
   PubMed Web of Science ®Google Scholar
• HanleyDAAdachiJDBellABrownVDenosumab: mechanism of action and clinical outcomesInt J Clin Pract201266121139114622967310
   PubMed Web of Science ®Google Scholar
• ManolagasSCBirth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosisEndocr Rev200021211513710782361
   PubMed Web of Science ®Google Scholar
• WeitzmannMNPacificiREstrogen deficiency and bone loss: an inflammatory taleJ Clin Invest200611651186119416670759
   PubMed Web of Science ®Google Scholar
• WongMHStocklerMRPavlakisNBisphosphonates and other bone agents for breast cancerCochrane Database Syst Rev20122CD00347422336790
   PubMed Web of Science ®Google Scholar
• RoodmanGDMechanisms of bone metastasisN Engl J Med2004350161655166415084698
   PubMed Web of Science ®Google Scholar
• MundyGRMetastasis to bone: causes, consequences and therapeutic opportunitiesNat Rev Cancer20022858459312154351
   PubMed Web of Science ®Google Scholar
• ColemanREMetastatic bone disease: clinical features, pathophysiology and treatment strategiesCancer Treat Rev200127316517611417967
   PubMed Web of Science ®Google Scholar
• KanisJAAssessment of Osteoporosis at the Primary Health Care LevelWHO Scientific Group Technical Report Available from: http://www.iofbonehealth.org/sites/default/files/WHO_Technical_Report-2007.pdf2007Accessed May 13, 2015
   Google Scholar
• JohnellOKanisJAAn estimate of the worldwide prevalence and disability associated with osteoporotic fracturesOsteoporos Int200617121726173316983459
   PubMed Web of Science ®Google Scholar
• GralowJRBiermannJSFarookiANCCN Task Force Report: Bone health in cancer careJ Natl Compr Canc Netw201311Suppl 3S1S5023997241
   PubMed Web of Science ®Google Scholar
• SeibelMJBiochemical markers of bone turnover: part I: biochemistry and variabilityClin Biochem Rev20052649712216648882
   PubMedGoogle Scholar
• US Department of Health and Human ServicesNational Hospital Discharge Survey2010 Available from: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHDS/NHDS_2010_Documentation.pdf2012Accessed February 11, 2016
   Google Scholar
• International Osteoporosis FoundationFacts and Statistics Available from: http://www.iofbonehealth.org/facts-statistics2015Accessed May 18, 2015
   Google Scholar
• FabianCJThe what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancerInt J Clin Pract200761122051206317892469
   PubMed Web of Science ®Google Scholar
• RizzoliRBodyJJDeCAGuidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paperOsteoporos Int201223112567257622270857
   PubMed Web of Science ®Google Scholar
• PerezEAJosseRGPritchardKIEffect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17J Clin Oncol200624223629363516822845
   PubMed Web of Science ®Google Scholar
• EastellRAdamsJEColemanREEffect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230J Clin Oncol20082671051105718309940
   PubMed Web of Science ®Google Scholar
• EastellRHannonRACuzickJEffect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)J Bone Miner Res20062181215122316869719
   PubMed Web of Science ®Google Scholar
• HoustonKEThomsonDBAromatase inhibitors: what is the true cost?Intern Med J201141213914022747552
   PubMed Web of Science ®Google Scholar
• ColemanREBanksLMGirgisSISkeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled studyLancet Oncol20078211912717267326
   PubMed Web of Science ®Google Scholar
• Arimidex Tamoxifen Alone or in Combination (ATAC) Trialists’ GroupForbesJFCuzickJEffect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialLancet Oncol200891455318083636
   PubMed Web of Science ®Google Scholar
• BliucDNguyenNDMilchVENguyenTVEismanJACenterJRMortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and womenJAMA2009301551352119190316
   PubMed Web of Science ®Google Scholar
• HowellACuzickJBaumMResults of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancerLancet20053659453606215639680
   PubMed Web of Science ®Google Scholar
• RabaglioMSunZPriceKNBone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trialAnn Oncol20092091489149819474112
   PubMed Web of Science ®Google Scholar
• LoveRRMazessRBBardenHSEffects of tamoxifen on bone mineral density in postmenopausal women with breast cancerN Engl J Med1992326138528561542321
   PubMed Web of Science ®Google Scholar
• DingHFieldTSBone health in postmenopausal women with early breast cancer: how protective is tamoxifen?Cancer Treat Rev200733650651317573199
   PubMed Web of Science ®Google Scholar
• PowlesTJHickishTKanisJATidyAAshleySEffect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal womenJ Clin Oncol199614178848558225
   PubMed Web of Science ®Google Scholar
• AgrawalAHannonRACheungKLEastellRRobertsonJFBone turnover markers in postmenopausal breast cancer treated with fulvestrant – a pilot studyBreast200918320420719464177
   PubMed Web of Science ®Google Scholar
• Zometa (zoledronic acid) injection [package insert]East Hanover, NJNovartis Pharmaceuticals Corp2015
   Google Scholar
• Aredia (pamidronate disodium for injection) for intravenous infusion [package insert]East Hanover, NJNovartis Pharmaceuticals Corp2011
   Google Scholar
• Xgeva (denosumab) injection, for subcutaneous use [package insert]Thousand Oaks, CAAmgen Inc62015
   Google Scholar
• GnantMRole of bisphosphonates in postmenopausal women with breast cancerCancer Treat Rev201440347648423906846
   PubMed Web of Science ®Google Scholar
• BoscoDOsteoporosis and aromatase inhibitors: experience and future prospectsClin Cases Miner Bone Metab201292899123087717
   PubMedGoogle Scholar
• RastelliALTaylorMEGaoFVitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trialBreast Cancer Res Treat2011129110711621691817
   PubMed Web of Science ®Google Scholar
• KhanQJReddyPSKimlerBFEffect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancerBreast Cancer Res Treat2010119111111819655244
   PubMed Web of Science ®Google Scholar
• NuzzoFGalloCLastoriaSBone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE studyAnn Oncol20122382027203322412041
   PubMed Web of Science ®Google Scholar
• ColemanRDeBREidtmannHZoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month resultsAnn Oncol201324239840523047045
   PubMed Web of Science ®Google Scholar
• BrufskyAMHarkerWGBeckJTFinal 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozoleCancer201211851192120121987386
   PubMed Web of Science ®Google Scholar
• LlombartAFrassoldatiAPaijaOImmediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trialClin Breast Cancer2012121404822014381
   PubMed Web of Science ®Google Scholar
• LesterJEDodwellDPurohitOPPrevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancerClin Cancer Res200814196336634218829518
   PubMed Web of Science ®Google Scholar
• McCloskeyEPatersonAKanisJTahtelaRPowlesTEffect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancerEur J Cancer201046355856520031392
   PubMed Web of Science ®Google Scholar
• EllisGKBoneHGChlebowskiRRandomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancerJ Clin Oncol200826304875488218725648
   PubMed Web of Science ®Google Scholar
• Van PoznakCHTeminSYeeGCAmerican Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancerJ Clin Oncol20112991221122721343561
   PubMed Web of Science ®Google Scholar
• HortobagyiGNTheriaultRLLiptonALong-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study GroupJ Clin Oncol1998166203820449626201
   PubMed Web of Science ®Google Scholar
• TheriaultRLLiptonAHortobagyiGNPamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study GroupJ Clin Oncol199917384685410071275
   PubMed Web of Science ®Google Scholar
• KohnoNAogiKMinamiHZoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trialJ Clin Oncol200523153314332115738536
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDKaminskiMZoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trialCancer J20017537738711693896
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDHDuganWJrZoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesionCancer20041001364314692022
   PubMed Web of Science ®Google Scholar
• BodyJJDielIJLichinitserMRIntravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastasesAnn Oncol20031491399140512954579
   PubMed Web of Science ®Google Scholar
• BodyJJDielIJLichinitzerMOral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studiesBr J Cancer20049061133113715026791
   PubMed Web of Science ®Google Scholar
• StopeckATLiptonABodyJJDenosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind studyJ Clin Oncol201028355132513921060033
   PubMed Web of Science ®Google Scholar
• LiptonAFizaziKStopeckATSuperiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trialsEur J Cancer201248163082309222975218
   PubMed Web of Science ®Google Scholar
• MillerPDBologneseMALewiekiEMEffect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trialBone200843222222918539106
   PubMed Web of Science ®Google Scholar
• BoneHGBologneseMAYuenCKEffects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone massJ Clin Endocrinol Metab201196497298021289258
   PubMed Web of Science ®Google Scholar
• GotterALWebberALColemanPJRengerJJWinrowCJInternational Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacologyPharmacol Rev201264338942022759794
   PubMed Web of Science ®Google Scholar
• HadjiPZillerMKiebackDGThe effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trialBreast200918315916419364653
   PubMed Web of Science ®Google Scholar
• KneisselMLuong-NguyenNHBaptistMEverolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclastsBone20043551144115615542040
   PubMed Web of Science ®Google Scholar
• GnantMBaselgaJRugoHSEffect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2J Natl Cancer Inst2013105965466323425564
   PubMedGoogle Scholar
• HadjiPTeschHFaschingPA4EVER: Does mTOR inhibition have a major clinical impact on bone health in postmenopausal women with hormone receptor positive (HR+) locally advanced breast cancer treated with everolimus (EVE) in combination with exemestane (EXE)?Presented at: San Antonio Breast Cancer Symposium12142013San Antonio, TX, USA abstr P6-06-32rt
   Google Scholar
• TeschHFaschingPAHadjiP4EVER – A phase IIIb, multi-center, open label study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer (BC) treated with everolimus (EVE) in combination with exemestane (EXE)Presented at: San Antonio Breast Cancer Symposium12122013San Antonio, TX, USA abstr OT2-6-09
   Google Scholar
• ClemonsMJCochraneBPondGRRandomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY studyBreast Cancer Res Treat2014146115316224924416
   PubMed Web of Science ®Google Scholar
• PaulDVukeljaSJHolmesFALetrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER-2 negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapyPresented at: San Antonio Breast Cancer Symposium12122013San Antonio, TX, USA abstr S3-07
   Google Scholar
• CostaLHarperPColemanRELiptonAAnticancer evidence for zoledronic acid across the cancer continuumCrit Rev Oncol Hematol201177Suppl 1S31S3721353179
   PubMed Web of Science ®Google Scholar
• GnantMMlineritschBSchippingerWEndocrine therapy plus zoledronic acid in premenopausal breast cancerN Engl J Med2009360767969119213681
   PubMed Web of Science ®Google Scholar
• DielIJSolomayerEFCostaSDReduction in new metastases in breast cancer with adjuvant clodronate treatmentN Engl J Med199833963573639691101
   PubMed Web of Science ®Google Scholar
• SaartoTBlomqvistCVirkkunenPElomaaIAdjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trialJ Clin Oncol2001191101711134190
   PubMed Web of Science ®Google Scholar
• ColemanRGnantMMorganGClezardinPEffects of bone-targeted agents on cancer progression and mortalityJ Natl Cancer Inst2012104141059106722752060
   PubMedGoogle Scholar
• ClezardinPBisphosphonates’ antitumor activity: an unravelled side of a multifaceted drug classBone2011481717920655399
   PubMed Web of Science ®Google Scholar
• OttewellPDDeuxBMonkkonenHDifferential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivoClin Cancer Res200814144658466618628481
   PubMed Web of Science ®Google Scholar
• ColemanREMarshallHCameronDBreast-cancer adjuvant therapy with zoledronic acidN Engl J Med2011365151396140521995387
   PubMed Web of Science ®Google Scholar
• ColemanREWinterMCCameronDThe effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancerBr J Cancer201010271099110520234364
   PubMed Web of Science ®Google Scholar
• PatersonAHAndersonSJLemberskyBCOral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trialLancet Oncol201213773474222704583
   PubMed Web of Science ®Google Scholar
• PowlesTPatersonSKanisJARandomized, placebo-controlled trial of clodronate in patients with primary operable breast cancerJ Clin Oncol200220153219322412149294
   PubMed Web of Science ®Google Scholar
• von MinckwitzGMobusVSchneeweissAGerman adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancerJ Clin Oncol201331283531353923980081
   PubMed Web of Science ®Google Scholar
• Ben-AharonIVidalLRizelSBisphosphonates in the adjuvant setting of breast cancer therapy – effect on survival: a systematic review and meta-analysisPLoS One201388e7004423990894
   PubMed Web of Science ®Google Scholar
• HeMFanWZhangXAdjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysisJ Hematol Oncol2013618024283946
   PubMed Web of Science ®Google Scholar
• ColemanRGnantMPatersonTEffects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: a meta-analysis of individual patient data from randomised trialsPresented at: San Antonio Breast Cancer Symposium12122013San Antonio, TX, USA abstr S4-S07
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)ColemanRPowlesTPatersonAAdjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trialsLancet2015386100011353136126211824
   PubMed Web of Science ®Google Scholar
• AftRNaughtonMTrinkausKEffect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trialLancet Oncol201011542142820362507
   PubMed Web of Science ®Google Scholar
• MaassNHarbeckNMundhenkeCEverolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR studyJ Cancer Res Clin Oncol2013139122047205624072232
   PubMed Web of Science ®Google Scholar
• CamponeMBachelotTGnantMEffect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 studyEur J Cancer201349122621263223735704
   PubMed Web of Science ®Google Scholar
• WallaceMSIrvingGCowlesVEGabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre studyClin Drug Investig20103011765776
   PubMed Web of Science ®Google Scholar
• ClemonsMGelmonKAPritchardKIPatersonAHBone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the artCurr Oncol201219525926823144574
   PubMed Web of Science ®Google Scholar
• DurieBGMKatzMCrowleyJOsteonecrosis of the jaw and bisphosphonatesN Engl J Med200535319910216000365
   PubMed Web of Science ®Google Scholar
• FuscoVGalassiCBerrutiADecreasing frequency of osteonecrosis of the jaw in cancer and myeloma patients treated with bisphosphonates: the experience of the oncology network of Piedmont and Aosta valley (north-Western Italy)ISRN Oncol2013201367202723533811
   PubMedGoogle Scholar
• Chavez-MacgregorMBrownELeiXBisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancerCancer2012118232633221590688
   PubMed Web of Science ®Google Scholar